Soliris growth trends
In 2016, Alexion Pharmaceuticals (ALXN) continued to witness solid uptake for Soliris. The growth was due to more newly diagnosed PNH (paroxysmal nocturnal hemoglobinuria) patients. The company is focusing on improving diagnostic mechanisms.
Soliris also witnessed strong demand in the AHUS (atypical hemolytic uremic syndrome) segment in 50 markets in the world. Alexion Pharmaceuticals thinks that the opportunity for Soliris in the AHUS segment is bigger than that in the PNH segment. To learn more about Soliris as a therapy for PNH, read Soliris Is Treating Major Rare Diseases around the World.
AHUS market opportunity
The above chart shows the growth opportunity for Soliris in the AHUS segment compared to the PNH segment.
Alexion Pharmaceuticals is also focused on driving the demand for the drug from Thrombotic Microangiopathy tested AHUS patients. The company plans to create awareness among physicians related to the debilitating effects of AHUS. Alexion Pharmaceuticals is also striving to enable AHUS patients get access to Soliris as a first-line treatment.
If the company manages to capitalize on the AHUS opportunity for Soliris, it could have a positive impact on the share prices of Alexion Pharmaceuticals as well as the SPDR S&P 500 ETF (SPY). Alexion Pharmaceuticals accounts for ~0.14% of SPY’s total portfolio holdings.
In 3Q16, a new method-of-use patent for Soliris in AHUS indication was added in the Orange book of patents. Combined with the composition of matter patent, orphan drug exclusivities, and regulatory data, the patent is expected to protect Soliris from generic competition from companies such as Mylan (MYL), Akorn (AKRX), and Teva Pharmaceuticals (TEVA) by 2032. Alexion Pharmaceuticals expects to receive more patents for Soliris in the US, European, and Japanese markets by 2018.
In the next part, we’ll analyze the growth trends for Strensiq in 2017.